Christopher G Twitty
Overview
Explore the profile of Christopher G Twitty including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
753
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Garris C, Arlauckas S, Kohler R, Trefny M, Garren S, Piot C, et al.
Immunity
. 2022 Sep;
55(9):1749.
PMID: 36103861
No abstract available.
2.
Lee J, Nguyen B, Mukhopadhyay A, Han M, Zhang J, Gujar R, et al.
Mol Ther Oncolytics
. 2022 May;
25:174-188.
PMID: 35592387
Clinical studies have demonstrated that local expression of the cytokine IL-12 drives interferon-gamma expression and recruits T cells to the tumor microenvironment, ultimately yielding durable systemic T cell responses. Interrogation...
3.
Han M, Nguyen B, Lee J, Browning E, Zhang J, Mukhopadhyay A, et al.
Mol Cancer Res
. 2022 Mar;
20(6):983-995.
PMID: 35302641
Implications: This DNA-encodable polyclonal T-cell stimulator (membrane-anchored anti-CD3 plasmid) may represent a key addition to intratumoral IL12 therapies in the clinic.
4.
Telli M, Nagata H, Wapnir I, Acharya C, Zablotsky K, Fox B, et al.
Clin Cancer Res
. 2021 Feb;
27(9):2481-2493.
PMID: 33593880
Purpose: Triple-negative breast cancer (TNBC) is an aggressive disease with limited therapeutic options. Antibodies targeting programmed cell death protein 1 (PD-1)/PD-1 ligand 1 (PD-L1) have entered the therapeutic landscape in...
5.
Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma
Algazi A, Twitty C, Tsai K, Le M, Pierce R, Browning E, et al.
Clin Cancer Res
. 2020 May;
26(12):2827-2837.
PMID: 32376655
Purpose: Tumors with low frequencies of checkpoint positive tumor-infiltrating lymphocytes (cpTIL) have a low likelihood of response to PD-1 blockade. We conducted a prospective multicenter phase II trial of intratumoral...
6.
Twitty C, Huppert L, Daud A
Curr Oncol Rep
. 2020 Feb;
22(3):25.
PMID: 32048065
Purpose Of Review: Recent developments in immunotherapy have transformed the landscape of melanoma therapy. Here, we review markers for response to immunotherapy. Recent Findings: Current immunotherapies disable immune checkpoints on...
7.
Greaney S, Algazi A, Tsai K, Takamura K, Chen L, Twitty C, et al.
Cancer Immunol Res
. 2019 Dec;
8(2):246-254.
PMID: 31852717
Whereas systemic IL12 is associated with potentially life-threatening toxicity, intratumoral delivery of IL12 through tavokinogene telseplasmid electroporation (tavo) is safe and can induce tumor regression at distant sites. The mechanism...
8.
Bhatia S, Longino N, Miller N, Kulikauskas R, Iyer J, Ibrani D, et al.
Clin Cancer Res
. 2019 Oct;
26(3):598-607.
PMID: 31582519
Purpose: IL12 promotes adaptive type I immunity and has demonstrated antitumor efficacy, but systemic administration leads to severe adverse events (AE), including death. This pilot trial investigated safety, efficacy, and...
9.
Garris C, Arlauckas S, Kohler R, Trefny M, Garren S, Piot C, et al.
Immunity
. 2018 Dec;
49(6):1148-1161.e7.
PMID: 30552023
Anti-PD-1 immune checkpoint blockers can induce sustained clinical responses in cancer but how they function in vivo remains incompletely understood. Here, we combined intravital real-time imaging with single-cell RNA sequencing...
10.
Lin A, Twitty C, Burnett R, Hofacre A, Mitchell L, Espinoza F, et al.
Mol Ther Nucleic Acids
. 2017 Mar;
6:221-232.
PMID: 28325288
Tumor cells express a number of immunosuppressive molecules that can suppress anti-tumor immune responses. Efficient delivery of small interfering RNAs to treat a wide range of diseases including cancers remains...